Prof. Peng and Arnold received funding from the UWM Research Foundation to investigate the in vivo efficacy of novel combination therapy for cancer using ROS-activated prodrugs and prooxidants.

Current cancer drugs most often do not distinguish between malignant cells and healthy cells thus leading to the many side effects seen during cancer chemotherapy. Dr. Peng’s group has designed patented cancer pro-drugs which are selectively activated by conditions that… Read More

A R15 grant from the National Cancer Institute was awarded to Prof. Xiaohua Peng titled “Novel DNA cross-linking agents and combination strategies for tumor-specific activation”

Cancer cells are in a state of increased basal oxidative stress due to their aberrant growth. As a result, cancer cells have elevated levels of reactive oxygen species (ROS) compared to normal cells. This feature has been employed to develop… Read More

MIDD member Karyn Frick was awarded a multimillion-dollar grant to study estrogenic regulation of the hippocampal ubiquitin-proteasome system and its role in memory and structural plasticity.

Memory impairment is a defining characteristic of many neuropsychiatric disorders, however, an understanding of the complex neural mechanisms regulating hippocampal memory formation remains elusive. To investigate this neural mechanism, the National Institute of Neurological Disorders and Stroke has awarded several… Read More